Premium
Hurdles and Leaps for Protein Therapeutics
Author(s) -
Kozlowski Steven,
Cherney Barry,
Donnelly Raymond P.
Publication year - 2009
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2009.05158.x
Subject(s) - leaps , drug development , cytokine , drug discovery , drug , proinflammatory cytokine , medicine , computational biology , biology , pharmacology , immunology , bioinformatics , inflammation , business , finance
Cytokines encompass a wide variety of proteins that can trigger many cellular activities. An important set of cytokines modulate inflammatory responses (inflammatory cytokines). These molecules have potent biological activities and have been a major focus for protein drug development. There have been both successes and failures in this area. Initial hurdles, such as limited manufacturing capacity, have now been largely overcome. However clinical development remains a challenge. On the basis of the history of cytokine therapeutics, a number of strategies for future drug development are considered.